XGene Regulatory Intelligence Platform
Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.
Abraxane was approved in 2005. The nab-technology platform — albumin-bound nanoparticles manufactured by high-pressure homogenization — is one of the most commercially validated nanomedicine platforms in oncology. The mechanism is understood: albumin's interaction with
View details →
Exosome drug delivery is simultaneously one of the most promising and most CMC-challenged platforms in pharmaceutical development. The biology is compelling — endogenous vesicle tropism, immune evasion, and natural cell-targeting properties that synthetic nanoparticles
View details → Radiopharmaceutical CMC shares almost nothing with standard pharmaceutical CMC except the regulatory framework it sits within. The drug substance is a radioisotope — its "purity" is measured in becquerels and percentages of radioactive decay
View details → The peptide therapeutics market has expanded dramatically — GLP-1 receptor agonists, integrin antagonists, antimicrobial peptides, cyclic peptides, and stapled peptides are in clinical development across virtually every therapeutic area. Fmoc solid-phase peptide synthesis is
View details → Oligonucleotide therapeutics have achieved commercial validation — multiple phosphorothioate ASOs, several GalNAc-conjugated siRNAs, and multiple aptamers are FDA-approved, and the pipeline is expanding rapidly. The solid-phase synthesis chemistry for oligonucleotide drug substances is reproducible,
View details → Every mRNA CMC program built in the last several years has been built on a vaccine foundation. The IVT process, the LNP formulation platform, the analytical methods, and the FDA reviewer experience all derive
View details → PROTACs are classified as small molecules for regulatory purposes. This classification creates a CMC illusion: because the drug substance is not a biologic, the CMC team believes the conventional small molecule regulatory playbook applies
View details → A photosensitizer drug product's therapeutic mechanism depends on a photophysical event — absorption of light at a specific wavelength followed by energy transfer to molecular oxygen, generating the singlet oxygen species that actually does
View details → A PROTAC is a small molecule in the regulatory sense — it is not a biologic, it does not require a BLA, and it files as an NDA under ICH Q6A. It is not
View details → An ASO n-1 shortmer is not a typical process impurity. It is a pharmacologically active sequence-truncated version of your drug substance that differs from the full-length ASO by the absence of one nucleotide. It
View details → Alnylam has four FDA-approved GalNAc-siRNA drugs. Their CMC frameworks are in FDA's review files. The FDA reviewer who evaluates your GalNAc-siRNA NDA will compare your CMC documentation to Givosiran, Lumasiran, Inclisiran, and Vutrisiran —
View details → Cap 1 mRNA is immunologically silent. Cap 0 mRNA triggers innate immune sensors. Uncapped mRNA does both — without the translational efficiency advantage. The ratio of cap 1 to cap 0 to uncapped mRNA
View details → Circular RNA has no 5' cap. It has no poly(A) tail. The analytical methods validated for linear mRNA drug substance — capping efficiency by LC-MS/MS, poly(A) tail length by CGE, integrity by full-length peak
View details → A base editor is a deaminase fused to a Cas9 nickase. A prime editor is a reverse transcriptase fused to a Cas9 nickase. Neither requires a double-strand DNA break. Neither has an approved drug
View details → Oncolytic viruses sit at an unusually demanding CMC intersection: the product must retain a defined viral identity and engineered genotype, reproduce consistently, express any therapeutic transgene as intended, demonstrate biological potency, and maintain an
View details →
Vowst received FDA approval in April 2023 — the first orally administered microbiome therapeutic for C. difficile recurrence prevention. Rebyota was approved in November 2022 as the first fecal microbiota product for rectal administration.
View details → A 3D-bioprinted scaffold delivering a drug is not a drug product with a device delivery system bolted on. It is a combination product in which the scaffold material, the fabrication process, the drug loading
View details → Every patient's neoantigen cancer vaccine has a different mRNA sequence. There is no reference standard, because the reference is the patient's own tumor mutational profile — and no two tumor mutational profiles are the
View details →